Some of the LSA genes have been shown to be overexpressed in advanced cancers and be associated with unfavorable clinical outcomes such as SOX11 [73, 74], PTPRN [75], PNCK [76] and HMGA2 [77–79]. This evidence concerns the gene HMGA2 and cancer.